HT
Therapeutic Areas
Neurophyxia Pipeline
| Drug | Indication | Phase |
|---|---|---|
| 2-iminobiotin (2-IB) | Cerebral hypoxia-ischemia following Stroke | Phase IIb/III |
Leadership Team at Neurophyxia
CP
Cacha Peeters-Scholte, MD, PhD
Co-founder & Chief Scientific Officer
IJ
Ir. Jan van der Hoeven
Chief Executive Officer
LG
Leo G. J. de Leede, PharmD, RPh, PhD
Chief Pharmaceutical Development Officer
DE
Drs. Elize van der Hoeven, PharmD
Chief Operation Officer